

Oncology Issues



ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20

Fighting the Good Fight

Lee E. Mortenson

 $\textbf{To cite this article:} \ \mathsf{Lee} \ \mathsf{E.} \ \mathsf{Mortenson} \ (1998) \ \mathsf{Fighting the Good} \ \mathsf{Fight}, \ \mathsf{Oncology} \ \mathsf{Issues}, \ 13:3, \ 7-7, \ \mathsf{Issues}, \ \mathsf$

DOI: <u>10.1080/10463356.1998.11904745</u>

To link to this article: https://doi.org/10.1080/10463356.1998.11904745

	Published online: 18 Oct 2017.
	Submit your article to this journal $oldsymbol{arGamma}$
ılıl	Article views: 1
a	View related articles ☑

HOT OFF THE PRESS!

Community Cancer Programs in the United States 1997-1998

The eighteenth edition of the Association of Community Cancer Centers' directory is now available. Copies have already been mailed to ACCC institutional members.

WHAT IS IT? The directory is a detailed reference of more than 500 medical centers, hospitals, and cancer clinics across the U.S. These ACCC member institutions treat 40 percent of all new cancer patients seen in the U.S. each year. Inside its 600+ pages you will find:

- An analysis of hospital cancer program trends over the past year
- Program data for each institution that include bed size, research components, ACoS approval, number of dedicated cancer unit beds, and number of new analytic cancer patients seen per year
- A detailed breakdown of radiation therapy equipment
- Which programs have a BMT unit
- The number of oncology staff, including physicians, nurses, and administrative staff
- Names of key oncology contacts
- A photograph and narrative description.

WHAT ELSE? ACCC members also include more than 300 individual members and 14 state oncology society chapters. You'll find names and addresses of these key contacts.

HOW CAN I ORDER A COPY?

The directory is \$50 for ACCC members (and other non-profit institutions) and \$150/copy for non-members.

Please send me ordering information for Community Cancer Programs in the United States 1997-1998.

Name	
Title	
Institution	
Address	
City/State	

Return to ACCC, 11600 Nebel St., Suite 201, Rockville, MD 20852-2557/Fax: 301-770-1949. FROM THE EDITOR



All that is necessary for the forces of evil to win in the world is for enough good men to do nothing.

—Edmund Burke

wenty thousand letters? That's the last best guess about the number of letters you and your colleagues sent to the Health Care Financing Administration (HCFA) about its proposed use of the Stark II regulations to impose actual acquisition costs on medical oncology practices. Although I'm not saying that HCFA is evil, a lack of understanding about the implications of its actions—the unintended consequences—can indeed be destructive. And, let's be clear, perhaps 70 percent of the letters received by HCFA and copied to members of Congress were from good women as well as good men.

There is no doubt that your strong response has alerted HCFA and many members of Congress that the idea of actual acquisition costs is ill considered. The final outcome remains to be seen, but a recent joint meeting with ONS and ACCC leaders and HCFA staff made it clear that HCFA now recognizes that its proposal is an inappropriate use of Stark II. I believe that HCFA will back off.

I wish I could say that the dark days are over, but they are not. Almost immediately several other attempts to cut chemotherapy costs surfaced, most from HCFA or HCFA Medicare medical directors. The first issue is a HCFA proposal for a single Ambulatory Payment Classification (APC) that will bundle nursing administration, chemotherapy, and supportive care drugs received in the hospital outpatient setting on the same day. This "single bucket" approach is

Fighting the Good Fight

by Lee E. Mortenson, D.P.A.

another ill-considered idea. Most chemotherapy drugs are high cost, sole source, with little room for discounting. There are substitutes, but they are not therapeutic equivalents.

The natural outcome of this proposal would be to give patients seen in hospital outpatient settings less effective drugs or fewer supportive care drugs. Moreover, this proposal is based on a 1996 drug formula. More than two dozen new drugs and/or indications have emerged in the last twelve to eighteen months, totally changing whatever average HCFA or anyone else attempts to formulate.

The second issue concerns proposed legislation suggesting that actual acquisition is a method of cost savings. The President in his budget, Senator Moynihan (D-N.Y.), Representative Stark (D-Calif.), and Representative Berry (D-Ark.) have all introduced such legislation, which they would like to see used to power their own agendas.

Then there are the Medicare medical directors who, through a variety of actions, appear to be attempting to dictate national payment policy, one state at a time.

So, good men and good women, it is obvious that when we recognize Burke's ageless concept and take action, we can have a significant effect. I believe that many times this year, we will need to pull together and confront the destructive forces. We can be heartened by our successes and cautious about our victories. Still, doing nothing is not in the nature of men and women in oncology who are born to be patient advocates. In case you are wondering, that's you and I and our many friends throughout the oncology community who continue to be willing to fight for quality cancer care.